Cas9 Stable Cell Line - Bewo

Cas9 Stable Cell Line - Bewo is a genetically engineered cell line derived from the human chorionic villus carcinoma cell line Bewo. This specialized cell line is engineered to stably express CRISPR-associated protein 9 (Cas9), a key component of the CRISPR-Cas9 genome editing system. Derived from human placental tissue, the Bewo cell line is of immense value in reproductive biology, oncology, and developmental biology research. Stable integration of Cas9 ensures sustained, long-term expression of the protein without the need for repeated transfections, significantly improving experimental reproducibility and efficiency. These cells retain the standard characteristics of Bewo cells, including epithelial-like morphology and hormone responsiveness, while providing a powerful platform for targeted gene modification.

Cas9 Stable Cell Line - Bewo holds broad promise for applications in biomedical research. Firstly, it serves as a powerful model for functional genomics, enabling researchers to perform precise gene knockout, knock-in, or transcriptional regulation within the context of placental and cancer biology. This is invaluable for studying genes associated with trophoblastic invasion, placental developmental disorders (e.g., preeclampsia), or oncogenic pathways. Furthermore, this cell line can facilitate rapid screening of therapeutic targets via CRISPR-based screening, thereby accelerating drug discovery. In CRISPR screening, guide RNA (gRNA) libraries can identify genes that influence drug sensitivity or resistance. In disease modeling, this cell line helps construct homologous cell lines with specific mutations to mimic pathologies such as choriocarcinoma or pregnancy disorders. Beyond basic research, this cell line also supports biomarker validation, gene therapy development, and toxicology studies because its stable Cas9 expression reduces variability compared to transient expression methods.